Mr. Chair, again, maybe I could start.
I think there are two sets of issues there.
One is what kind of substances we would think about adding to the watch-list. That goes back to the answer I gave to MP Deltell about the difference between a hazard-based and risk-based assessments. If a substance has hazardous characteristics but at the moment there is no use that is problematic, we identify that in our risk assessments, but we then say that it is not toxic, that it doesn't test for toxic—